Mydecine Shares Suspended on Aquis Market
Company Announcements

Mydecine Shares Suspended on Aquis Market

Story Highlights

Mydecine Innovations Group (TSE:MYCO) has released an update.

Mydecine Innovations Group, a biotech firm focused on developing treatments for mental health disorders, has had its shares suspended from trading on the Aquis Growth Market due to non-payment of exchange fees. The company, which is pioneering next-generation medications including psychedelic compounds for conditions like PTSD and nicotine addiction, made the announcement and acknowledged its responsibility.

For further insights into TSE:MYCO stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskMydecine Completes Key Financial Filings
TipRanks Canadian Auto-Generated NewsdeskMydecine Delays Financial Filings, Postpones AGM
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App